Best Neuroblastoma Treatment Doctors in India

What Parents of a Child with Neuroblastoma Worry About Most

Parents whose child is diagnosed with neuroblastoma face the hardest weeks of their lives. The disease behaves very differently depending on age, stage, and biology. Very young infants sometimes need only observation, while older children with high-risk disease need eighteen months of intensive multimodality treatment. The first questions are whether the tumour is low, intermediate, or high-risk, whether MYCN amplification is present, whether surgery alone will be enough, and whether the child will need a bone marrow transplant.

How Neuroblastoma Is Diagnosed

Ultrasound, computed tomography, or magnetic resonance imaging identifies an abdominal, adrenal, or paraspinal mass. Urine catecholamines (vanillylmandelic acid and homovanillic acid) are usually elevated. Tissue biopsy confirms the diagnosis. Staging uses metaiodobenzylguanidine (MIBG) scan, which is specific for neuroblastoma, and bone marrow biopsy. Risk stratification depends on age, stage, MYCN status, ploidy, and histology. Children under one year with localised disease often have very favourable outlooks.

Treatment Options for Neuroblastoma in India

Low-risk disease may need only surgery or observation. Intermediate-risk disease is treated with surgery and moderate chemotherapy. High-risk disease (older child, metastatic spread, MYCN amplification) needs induction chemotherapy with cisplatin, etoposide, doxorubicin, cyclophosphamide, and vincristine, followed by surgical resection, high-dose chemotherapy with autologous stem cell rescue, radiation to the primary site, and immunotherapy with dinutuximab or naxitamab combined with retinoic acid maintenance. Metaiodobenzylguanidine therapy with iodine-131 is available at select centres for relapsed disease. Fortis Memorial Research Institute, Medanta, Apollo, BLK-Max, and Tata Memorial run paediatric oncology programmes capable of full high-risk neuroblastoma protocols including immunotherapy.

Recovery, Success Rates, and Follow-Up

Low-risk neuroblastoma has over ninety-five percent five-year survival. Intermediate-risk disease has around ninety percent survival. High-risk neuroblastoma survival has improved from twenty percent to fifty percent with modern multimodality treatment including immunotherapy. Total treatment for high-risk disease runs eighteen months: six cycles of induction over six months, autologous transplant with three to four weeks in hospital, radiation, and a year of immunotherapy. Follow-up scans and urine catecholamines continue for at least five years.

How to Choose the Right Doctor

Look for a paediatric hemato-oncologist with focused neuroblastoma experience and access to autologous stem cell transplant and dinutuximab immunotherapy. Ask how many high-risk neuroblastoma cases the team treats yearly, whether metaiodobenzylguanidine scanning is available, whether the centre has paediatric surgical oncology and paediatric intensive care, and whether the radiation oncology team has experience with paediatric planning.

Support for International Patients

The full high-risk neuroblastoma protocol in India, including immunotherapy, costs a fraction of equivalent care in the United Kingdom, United States, or Middle East. Cancer Rounds arranges the medical visa invitation letter, airport pickup, family accommodation near the treatment hospital for the long stay, multilingual support in eleven plus languages, and full coordination with the paediatric oncology unit. Families from Nigeria, Bangladesh, Kenya, Ethiopia, Iraq, Oman, the United Arab Emirates, and other countries bring children to India regularly for neuroblastoma care.

Frequently Asked Questions

Is neuroblastoma curable?

Low and intermediate-risk neuroblastoma has cure rates over ninety percent. High-risk neuroblastoma cure rates have improved from twenty percent to around fifty percent with modern induction, autologous transplant, radiation, and immunotherapy.

What is MYCN amplification?

MYCN is a gene whose amplification in neuroblastoma cells indicates aggressive disease. Children with MYCN amplification are classified as high-risk regardless of age or stage and need full intensive multimodality treatment.

What is dinutuximab?

Dinutuximab is an immunotherapy antibody that targets GD2 on neuroblastoma cells. Given after autologous transplant along with retinoic acid, it has improved survival in high-risk neuroblastoma significantly and is available at major Indian paediatric oncology centres.

Do all children need a transplant?

No. Only high-risk neuroblastoma needs high-dose chemotherapy with autologous stem cell rescue. Low and intermediate-risk disease is treated with surgery and moderate chemotherapy without transplant.

What is a metaiodobenzylguanidine scan?

Metaiodobenzylguanidine scanning is a nuclear medicine test that highlights neuroblastoma cells specifically. It is used at diagnosis to find all tumour sites, during treatment to assess response, and afterwards to detect relapse. Iodine-131-labelled metaiodobenzylguanidine can also be used as targeted therapy.

How long does treatment take?

High-risk protocols run around eighteen months from start to finish. Low and intermediate-risk treatment is shorter, often three to six months. Families should plan for a long stay if travelling internationally for high-risk treatment.